PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Novel Therapies Vital to Counter the Challenge from Generics in the U.S. Rheumatoid Arthritis Market Finds Frost & Sullivan - Rise in incidence of rheumatoid arthritis from 2.4 million in 2010 to 2.6 million in 2017 encourages development of new drugs
Novel Therapies Vital to Counter the Challenge from Generics in the U.S. Rheumatoid Arthritis Market Finds Frost & Sullivan

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2011/09/29 - Rise in incidence of rheumatoid arthritis from 2.4 million in 2010 to 2.6 million in 2017 encourages development of new drugs.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The unmet need for a convenient and safe rheumatoid arthritis (RA) treatment option without adverse side effects has set the stage for a spate of drug launches in the near future. As a result of this demand, some of the current pipeline drugs have the potential to be blockbusters, especially the oral treatments in late-stage development.

In 2010, the American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) revised the 1987 classification criteria for RA to enable early detection. The new classification facilitates diagnosing RA patients and thereby, gives a boost to the treatment market.

New analysis from Frost & Sullivan's (pharma.frost.com) U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments research finds that the market for RA (biologics and new treatments) earned revenues of $5.78 billion in 2010. This is expected to increase to $8.34 billion in 2017.

If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers[.]frost.com, with your full name, company name, title, telephone number, company email address, company Website, city, state and country.

The first-line of biologic agents, after methotrexate, is Enbrel and Humira; Remicade, Simponi, and Cimzia are additional anti-tumor necrosis factor (TNF) options. If patients experience TNF failure, physicians then will either change to a second anti-TNF or switch classes to Orencia, Actemra or Rituxan.

Compounds in the late stages of development include CP-690,550 and fostamatinib disodium. CP-690,550 (tasocitinib) is a Janus kinases (JAK) 1/3 inhibitor, which is expected to be the first oral compound to reach the RA market for disease-modifying antirheumatic drugs (DMARDs) inadequate responders (IR). As tasocitinib is being developed as an oral medication, it has the potential to be used ahead of TNF antagonists in the RA treatment paradigm.

R788 is also being evaluated as an oral twice-a-day treatment, as it can be an improvement on the expensive TNF blockers that are delivered subcutaneously or intravenously and have side effects.

Small molecules such as Pfizer's CP-690,550 can have a big impact on the market if they demonstrate positive safety and efficacy data due to the convenience and low cost of oral therapy.

"With the number of biologics on the market and in development for RA, the RA treatment market is becoming crowded," said Frost & Sullivan Industry Manager Jennifer Brice. "Biologics entering this market must be able to show efficacy and safety data that is comparable, if not superior, to TNF blockers to gain any market share."

Currently, many biologics such as TNF antagonists are associated with severe adverse events such as infections and lymphoma. Safety concerns and the annual cost of RA treatment, which can vary from $10,000 to $20,000, can restrain patients–especially uninsured ones–from opting for biologics.

With the patent of the first-line biologic, Enbrel, due to expire in 2012, the entry of biosimilars could be a game changer. Although they can increase adoption rates and availability, these low-priced generics could reduce revenue generation rates.

If adequate reimbursements are not available, patients may choose biosimilars over expensive novel therapies, which will slow down the market's growth rate. Tight budgets from insurance companies will further restrict the use of novel therapies and encourage generics.

"Biosimilars are expected to influence the U.S. market in the next three years to four years," said Brice. "To fight back the challenge from these generics, pharmaceutical and biotech companies need to continue to address unmet needs in the treatment of RA by developing novel medications."

U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments is part of the Pharmaceuticals & Biotechnology Growth Partnership Services program, which also includes research in the following markets: Rheumatoid Arthritis Therapeutics Market in Australia, Rheumatoid Arthritis Therapeutics Market in Japan, Rheumatoid Arthritis Therapeutics Market in India, and Rheumatoid Arthritis Therapeutics Market in China. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments / N96E

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Novel Therapies Vital to Counter the Challenge from Generics in the U.S. Rheumatoid Arthritis Market Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Britni Myers 
210-477-8481 britni.myers[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)